Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6210737 | 0.98 | PNMT (0.49) | PNMTADRA2ASIRT2CA12CA1 | |
| SCHEMBL541593 | 0.95 | CA12 (0.54) | PNMTADRA2ASIRT2CA12CA1 | |
| SCHEMBL27599386 | 0.91 | CA12 (0.50) | PNMTADRA2ASIRT2CA12CA1 | |
| SCHEMBL200716 | 0.88 | PNMT (0.58) | PNMTADRA2ASIRT2CA12CA1 | |
| SCHEMBL397538 | 0.87 | PNMT (0.50) | PNMTADRA2ASIRT2CA12CA1 | |
| Ammonia Solution, Strong SCHEMBL28209706 | 0.87 | PNMT (0.57) | PNMTADRA2ASIRT2CA12CA1 | |
| Methane SCHEMBL27508397 | 0.87 | PNMT (0.57) | PNMTADRA2ASIRT2CA12CA1 | |
| SCHEMBL27408384 | 0.84 | PNMT (0.54) | PNMTADRA2ASIRT2MAPTMEN1 | |
| SCHEMBL29581896 | 0.82 | PNMT (0.51) | PNMTADRA2ASIRT2CA12CA1 | |
| SCHEMBL395008 | 0.82 | PNMT (0.51) | PNMTADRA2ASIRT2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107652303-B | Novel thienopyrimidine derivatives, preparation method and therapeutic use thereof | 赛诺菲 | 2020-08-04 | — | — | CN | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-6972286-B2 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | PHARMACIA AND UPJOHN COMPANY (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-23 | — | — | US | disclosed |
| US-20040176609-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1337530-A1 | OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020133021-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | PHARMACIA & UPJOHN COMPANY | 2002-09-19 | — | — | US | disclosed |
| WO-2002059115-A1 | OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | PNMT 2981/4885ADRA2A 2163/4885SIRT2 4616/4885 |
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA2, CHRNA5, CHRNA10 | PNMT 315/4885ADRA2A 197/4885SIRT2 631/4885 |
| US-20020133021-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | PNMT 4235/4885ADRA2A 4476/4885SIRT2 628/4885 |
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | PNMT 4235/4885ADRA2A 4476/4885SIRT2 628/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | PNMT 2981/4885ADRA2A 2163/4885SIRT2 4616/4885 |
| US-20040176609-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | PNMT 4235/4885ADRA2A 4476/4885SIRT2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.